Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

ODYSSEY Trial Team

Résultat de recherche › examen par les pairs

19 Citations (Scopus)

Empreinte numérique

Plonger dans les sujets de recherche 'Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial'. Ensemble, ils forment une empreinte numérique unique.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology